Title : CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer. Language : English Author, co-author : Baron, Frédéric [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >] Copizza, Sandra [> > > >] Baudoux, Etienne [Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire >] Jerusalem, Guy [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >] Fillet, Georges [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >] Beguin, Yves [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >] Publication date : 2004 Journal title : Haematologica Publisher : Ferrata Storti Foundation Volume : 89 Issue/season : 9 Pages : 1146-8 Audience : International ISSN : 0390-6078 e-ISSN : 1592-8721 City : Pavia Country : Italy Keywords : [en] Adult ; Antigens, CD34/analysis ; Antineoplastic Combined Chemotherapy Protocols/economics/therapeutic use ; Breast Neoplasms/drug therapy/economics/surgery ; Cell Count ; Combined Modality Therapy/economics ; Costs and Cost Analysis ; Drug Costs ; Fees and Charges ; Female ; Hospital Costs ; Humans ; Middle Aged ; Peripheral Blood Stem Cell Transplantation/economics ; Transplantation, Autologous/economicsAbstract : [en] We assessed the effect of CD34+ cell dose on costs in breast cancer patients undergoing autologous peripheral blood stem cell (PBSC) transplantation. Mean hospitalization costs were 26,992.9+/-9582.9 for patients receiving a CD34+ cell dose <5 x 10(6) cells/kg versus 22,339.4+/- 5471.1 for those receiving >5 x 10(6) CD34+ cells/kg (p=0.0065).Permalink : http://hdl.handle.net/2268/6274 
[Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
